CoChat

CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure

Open access

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 3 of the 3 sources its claims cite were checked for support.

Abstract

CagriSema is a combination of amylin (cagrilintide) and glucagon-like peptide-1 (semaglutide) analogues being developed for weight management. Here, we show that CagriSema blunts metabolic adaptation in rats. Quantifying CagriSema's action on energy intake and expenditure in rats we observe 12% weight loss with a 39% reduction in food intake. By contrast, pair-feeding causes less-pronounced weight loss, while weight matching requires a 51% decrease in food intake. Therefore, approximately one-third of CagriSema's weight loss efficacy arises from an effect on energy expenditure, the blunting of metabolic adaptation, which contributes to the successful treatment of obesity.

Overview

CoChat Summary

## TL;DR

In diet-induced obese male rats, CagriSema produced about 12% weight loss while reducing food intake by 39%, and the authors estimate that roughly one-third of its weight-loss effect came from preserving energy expenditure. Compared with caloric restriction matched for body weight, CagriSema blunted metabolic adaptation and maintained total energy expenditure closer to vehicle levels.

## Key findings

  • After 21 days, vehicle-adjusted weight loss was ~12% in the CagriSema (CS) and weight-matched (WM) rats, but only ~8% in pair-fed (PF) rats.
  • CS treatment reduced cumulative energy intake by 39%, whereas WM rats required a 51% reduction in energy intake to achieve the same weight loss; cumulative total energy expenditure was similar in vehicle and CS but fell by 17% in WM.
  • Based on the area between the CS and PF curves, 28% of the weight loss was attributed to energy expenditure and 72% to energy intake; by 3 weeks, the energy-expenditure contribution reached 34%.
  • In pooled analysis of 145 rats, final total energy expenditure did not differ between vehicle and drug-treated groups, but was greater than in calorically restricted rats (V versus WM + PF, P < 0.0001; CS + C + S versus WM + PF, P < 0.0001; CS + C + S versus V, P = 0.97).

## Methods

  • Diet-induced obese male Sprague Dawley rats were studied in five independent energy-expenditure experiments; treatments included vehicle, CagriSema, cagrilintide alone, semaglutide alone, pair-feeding, and weight-matching.
  • Rats were housed under controlled light/dark and temperature conditions, and energy intake, total energy expenditure, respiratory exchange ratio, body weight, body composition, and core body temperature were measured; one pooled analysis combined 145 rats (vehicle n = 38, drug n = 57, calorie restriction n = 50).
  • The main analyses used ANOVA, ANCOVA, mixed-model ANCOVA, and differential expression analysis of liver and skeletal muscle RNA-seq data; pathway enrichment was performed on significant genes.

## Limitations

  • The paper states that “further testing” is needed in longer studies, in females, across other diets and species, and in species without substantial brown adipose thermogenesis.
  • It also states that the human relevance remains unproven; the cited human support is from a clinical study of a different drug and is noted as being hampered by lack of weight matching in the control group.
  • Evident from the text: the study is in male rats only, so sex differences were not assessed.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s42255-025-01324-8

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 CagriSema drives weight loss by acting on both EI and EE. a, Study design. b, Baseline body weight (BW), fat mass (FM) and fat free mass (FFM). c, Body weight time course during treatment. d, Change in body weight, fat mass and fat free mass between day −5 and day 21. e,f, Cumulative energy intake (EI). g,h, Cumulative total energy expenditure (TEE). i–l, Daily EI. m–p, Daily TEE. q–t, Respiratory exchange ratio (RER). u–x, Light phase body temperature. y–b′, Dark phase body temperature. In i–b′, each row shows the time course followed by the change from baseline (mean of days −3 to −1) to the mean of days 1–3, 7–9 or 18–20, as indicated. A dashed line indicates the first day of treatment. Body temperature is from a cohort detailed in Extended Data Fig. 3. Data are mean ± s.e.m., n = 10 or 11 per group (b–t) and n = 4 or 5 per group (u–b′). P values from one-way ANOVA with Tukey post hoc testing. VCO2, rate of CO2 production; VO2, rate of O2 consumption; MRS, magnetic resonance spectroscopy. Source data
Fig. 1 CagriSema drives weight loss by acting on both EI and EE. a, Study design. b, Baseline body weight (BW), fat mass (FM) and fat free mass (FFM). c, Body weight time course during treatment. d, Change in body weight, fat mass and fat free mass between day −5 and day 21. e,f, Cumulative energy intake (EI). g,h, Cumulative total energy expenditure (TEE). i–l, Daily EI. m–p, Daily TEE. q–t, Respiratory exchange ratio (RER). u–x, Light phase body temperature. y–b′, Dark phase body temperature. In i–b′, each row shows the time course followed by the change from baseline (mean of days −3 to −1) to the mean of days 1–3, 7–9 or 18–20, as indicated. A dashed line indicates the first day of treatment. Body temperature is from a cohort detailed in Extended Data Fig. 3. Data are mean ± s.e.m., n = 10 or 11 per group (b–t) and n = 4 or 5 per group (u–b′). P values from one-way ANOVA with Tukey post hoc testing. VCO2, rate of CO2 production; VO2, rate of O2 consumption; MRS, magnetic resonance spectroscopy. Source dataCC BY-NC-ND · PubMed Central
Fig. 2 Cagrilintide and semaglutide act individually on both EI and EE. a, Study design. b, Baseline body weight (BW), fat mass (FM) and fat free mass (FFM). c, Body weight time course during treatment. d, Change in body weight, fat mass and fat free mass between day −6 and day 22. e,f, Cumulative energy intake (EI). g,h, Cumulative total energy expenditure (TEE). i–l, Daily EI. m–p, Daily TEE. q–t, RER. In i-t, each row shows the time course followed by the change from baseline (mean of days −3 to −1) to the mean of days 1–3, 7–9 or 18–20, as indicated. A dashed line indicates the first day of treatment. Data are mean ± s.e.m., n = 8 per group. P values from one-way ANOVA with Tukey post hoc testing. Rate of CO2 production; VO2, rate of O2 consumption. MRS, magnetic resonance spectroscopy. Source data
Fig. 2 Cagrilintide and semaglutide act individually on both EI and EE. a, Study design. b, Baseline body weight (BW), fat mass (FM) and fat free mass (FFM). c, Body weight time course during treatment. d, Change in body weight, fat mass and fat free mass between day −6 and day 22. e,f, Cumulative energy intake (EI). g,h, Cumulative total energy expenditure (TEE). i–l, Daily EI. m–p, Daily TEE. q–t, RER. In i-t, each row shows the time course followed by the change from baseline (mean of days −3 to −1) to the mean of days 1–3, 7–9 or 18–20, as indicated. A dashed line indicates the first day of treatment. Data are mean ± s.e.m., n = 8 per group. P values from one-way ANOVA with Tukey post hoc testing. Rate of CO2 production; VO2, rate of O2 consumption. MRS, magnetic resonance spectroscopy. Source dataCC BY-NC-ND · PubMed Central
Fig. 3 Prevention of metabolic adaptation is responsible for close to one-third of CagriSema-induced weight loss. a,b, Contributions of energy intake (EI) and energy expenditure (EE) to body weight (BW) loss. Data are taken from Fig. 1c. c–g, Effect of vehicle (V), drug (CS + C + S) or caloric restriction (WM + PF) treatments on final BW, EE and EI, and on the changes in these parameters. e–g, Dotted lines are at the zero of each axis (represent no changes). h, Plasma leptin levels after the indicated treatments (taken data from Fig. 1 and Extended Data Figs. 1, 2 and 3). i,j, Upregulated and downregulated genes by treatment. Pathway enrichment analysis from liver can be found in Extended Data Fig. 7. Detailed statistical analyses are given in Extended Data Table 2 and Supplementary Table 1. Group size: a,b, n = 8; c–g, n = 38 (V), n = 57 (CS + C + S), n = 50 (WM + PF); h, n = 40 (V), n = 35 (CS), n = 34 (WM); i,j, n = 4 (V, CS and WM). Data are presented as mean ± s.e.m. (a), absolute numbers (b, i and j) and as regression lines with 95% confidence bands (c–h). Source data
Fig. 3 Prevention of metabolic adaptation is responsible for close to one-third of CagriSema-induced weight loss. a,b, Contributions of energy intake (EI) and energy expenditure (EE) to body weight (BW) loss. Data are taken from Fig. 1c. c–g, Effect of vehicle (V), drug (CS + C + S) or caloric restriction (WM + PF) treatments on final BW, EE and EI, and on the changes in these parameters. e–g, Dotted lines are at the zero of each axis (represent no changes). h, Plasma leptin levels after the indicated treatments (taken data from Fig. 1 and Extended Data Figs. 1, 2 and 3). i,j, Upregulated and downregulated genes by treatment. Pathway enrichment analysis from liver can be found in Extended Data Fig. 7. Detailed statistical analyses are given in Extended Data Table 2 and Supplementary Table 1. Group size: a,b, n = 8; c–g, n = 38 (V), n = 57 (CS + C + S), n = 50 (WM + PF); h, n = 40 (V), n = 35 (CS), n = 34 (WM); i,j, n = 4 (V, CS and WM). Data are presented as mean ± s.e.m. (a), absolute numbers (b, i and j) and as regression lines with 95% confidence bands (c–h). Source dataCC BY-NC-ND · PubMed Central
Extended Data Fig. 1 Reproduction of main Fig. 1 results in an independent cohort. (a) Study design. Treatments were vehicle (V), CagriSema (CS, 2 + 2 nmol/kg), and calorie-restricted to match the weight of the CS rats (weight matched, WM). (b) Body weight, fat mass and fat free mass at day −5. (c) Body weight time course, (d) change in body weight, fat mass (FM), and fat free mass (FFM) from day −5 to day 21. (e, f) Cumulative energy intake and (g, h) cumulative total energy expenditure (TEE). (i-l) Energy intake, (m-p) TEE, (q-t) dark phase EE, (u-x) light phase EE, (z-ab) respiratory exchange ratio (RER). In each set, the time course is followed by the change from baseline (mean of days −3 to −1) to the mean of days 1-3, 7-9, and 18-20, as indicated. Data are mean ± SEM, n = 10 (V) or n = 11 (CS and WM); P values from one-way ANOVA with Tukey post hoc testing.
Extended Data Fig. 1 Reproduction of main Fig. 1 results in an independent cohort. (a) Study design. Treatments were vehicle (V), CagriSema (CS, 2 + 2 nmol/kg), and calorie-restricted to match the weight of the CS rats (weight matched, WM). (b) Body weight, fat mass and fat free mass at day −5. (c) Body weight time course, (d) change in body weight, fat mass (FM), and fat free mass (FFM) from day −5 to day 21. (e, f) Cumulative energy intake and (g, h) cumulative total energy expenditure (TEE). (i-l) Energy intake, (m-p) TEE, (q-t) dark phase EE, (u-x) light phase EE, (z-ab) respiratory exchange ratio (RER). In each set, the time course is followed by the change from baseline (mean of days −3 to −1) to the mean of days 1-3, 7-9, and 18-20, as indicated. Data are mean ± SEM, n = 10 (V) or n = 11 (CS and WM); P values from one-way ANOVA with Tukey post hoc testing.CC BY-NC-ND · PubMed Central
Extended Data Fig. 2 No effect of treatment with CagriSema on physical activity. (a) Study design. Treatments are vehicle (V), CagriSema (CS, 2 + 2 nmol/kg), and calorie-restricted to match the weight of the CS rats (weight matched, WM). (b) Body weight, fat mass and fat free mass at day −6. (c) Body weight time course, (d-f) change in (d) body weight, (e) fat mass, and (f) fat free mass from day −6 to day 6 and day 28. (g, h) Cumulative energy intake. (i) Baseline physical activity time course (days −4 to 0). Dark phase is indicated by shading. (j) Baseline dark and light phase activity levels. (k) Activity level time course on treatment days 22 to 26. (l) Treated dark and light phase activity levels. Data are mean ± SEM, n = 10/group, P values from one-way ANOVA with Tukey post hoc testing.
Extended Data Fig. 2 No effect of treatment with CagriSema on physical activity. (a) Study design. Treatments are vehicle (V), CagriSema (CS, 2 + 2 nmol/kg), and calorie-restricted to match the weight of the CS rats (weight matched, WM). (b) Body weight, fat mass and fat free mass at day −6. (c) Body weight time course, (d-f) change in (d) body weight, (e) fat mass, and (f) fat free mass from day −6 to day 6 and day 28. (g, h) Cumulative energy intake. (i) Baseline physical activity time course (days −4 to 0). Dark phase is indicated by shading. (j) Baseline dark and light phase activity levels. (k) Activity level time course on treatment days 22 to 26. (l) Treated dark and light phase activity levels. Data are mean ± SEM, n = 10/group, P values from one-way ANOVA with Tukey post hoc testing.CC BY-NC-ND · PubMed Central
Extended Data Fig. 3 Characteristics of rats treated with CagriSema for body temperature measurement. (a) Study design during indirect calorimetry. Treatments are vehicle (V), CagriSema (CS, 2 + 2 nmol/kg), and calorie-restricted to match the weight of the CS rats (weight matched, WM). (b) Body weight, fat mass and fat free mass at day −5. (c) Body weight time course, (d) changes in body weight, fat mass, and fat free mass from day −5 to 26. (e, f) Cumulative energy intake and (g, h) cumulative total energy expenditure (TEE). (i-l) Daily energy intake, (m-p) daily TEE, and (q-t) respiratory exchange ratio (RER). Body temperature dark or light phase (12 h bins) are in main Fig. 1u-ab. Data are mean ± SEM, n = 8/group. P-values from one-way ANOVA with Tukey post hoc testing.
Extended Data Fig. 3 Characteristics of rats treated with CagriSema for body temperature measurement. (a) Study design during indirect calorimetry. Treatments are vehicle (V), CagriSema (CS, 2 + 2 nmol/kg), and calorie-restricted to match the weight of the CS rats (weight matched, WM). (b) Body weight, fat mass and fat free mass at day −5. (c) Body weight time course, (d) changes in body weight, fat mass, and fat free mass from day −5 to 26. (e, f) Cumulative energy intake and (g, h) cumulative total energy expenditure (TEE). (i-l) Daily energy intake, (m-p) daily TEE, and (q-t) respiratory exchange ratio (RER). Body temperature dark or light phase (12 h bins) are in main Fig. 1u-ab. Data are mean ± SEM, n = 8/group. P-values from one-way ANOVA with Tukey post hoc testing.CC BY-NC-ND · PubMed Central
Extended Data Fig. 4 Low efficacy of the individual CagriSema active agents. (a) Study design during indirect calorimetry. Treatments are vehicle (V), cagrilintide (C, 2 nmol/kg), semaglutide (S, 2 nmol/kg), and calorie-restricted to match the weight of the CS rats (weight matched, WM). (b) body weight, fat mass and fat free mass at day −5. (c) Body weight time course. (d) change in fat mass and fat free mass from day −5 to 21. (e, f) Cumulative energy intake and (g, h) cumulative total energy expenditure (TEE). (i-l) Daily energy intake, (m-p) daily TEE, and (q-t) respiratory exchange ratio (RER). In each set, the time course is followed by the change from baseline (mean of days −3 to −1) to the mean of days 1-3, 7-9, and 18-20, as indicated. Data are mean ± SEM, n = 6-8/group.
Extended Data Fig. 4 Low efficacy of the individual CagriSema active agents. (a) Study design during indirect calorimetry. Treatments are vehicle (V), cagrilintide (C, 2 nmol/kg), semaglutide (S, 2 nmol/kg), and calorie-restricted to match the weight of the CS rats (weight matched, WM). (b) body weight, fat mass and fat free mass at day −5. (c) Body weight time course. (d) change in fat mass and fat free mass from day −5 to 21. (e, f) Cumulative energy intake and (g, h) cumulative total energy expenditure (TEE). (i-l) Daily energy intake, (m-p) daily TEE, and (q-t) respiratory exchange ratio (RER). In each set, the time course is followed by the change from baseline (mean of days −3 to −1) to the mean of days 1-3, 7-9, and 18-20, as indicated. Data are mean ± SEM, n = 6-8/group.CC BY-NC-ND · PubMed Central
Extended Data Fig. 5 Plasma concentrations ketone-bodies, glucose, glucagon, lipids, insulin, leptin, and liver inflammation markers. Concentrations after 5-6 h fast. (a): Leptin, (b): Cholesterol, (c): Free fatty acids, (d): Glucose, (e): Glucagon, (f) Glycerol, (g): High-density lipoprotein (HDL), (h): Triglycerides, (i): Insulin, (j): 3-hydroxybuturate (3HB), (k) alanine transaminase (ALT), and (l) aspartate transaminase (AST). Data (all except leptin) are pooled from the experiments reported in main Fig. 1 and Extended Data Fig. 1). Leptin are from main Fig. 1, Extended Data Figs. 1, 2, 3, and 4). Data are mean ± SEM, n (all except leptin: V = 18, CS and WM = 19. n (leptin): V = 40, CS = 35, and WM = 34. Statistical significance was tested by One-way ANOVA followed by Tukey post hoc test. Colours: White: vehicle, Dark blue: CagriSema, and grey: weight matched.
Extended Data Fig. 5 Plasma concentrations ketone-bodies, glucose, glucagon, lipids, insulin, leptin, and liver inflammation markers. Concentrations after 5-6 h fast. (a): Leptin, (b): Cholesterol, (c): Free fatty acids, (d): Glucose, (e): Glucagon, (f) Glycerol, (g): High-density lipoprotein (HDL), (h): Triglycerides, (i): Insulin, (j): 3-hydroxybuturate (3HB), (k) alanine transaminase (ALT), and (l) aspartate transaminase (AST). Data (all except leptin) are pooled from the experiments reported in main Fig. 1 and Extended Data Fig. 1). Leptin are from main Fig. 1, Extended Data Figs. 1, 2, 3, and 4). Data are mean ± SEM, n (all except leptin: V = 18, CS and WM = 19. n (leptin): V = 40, CS = 35, and WM = 34. Statistical significance was tested by One-way ANOVA followed by Tukey post hoc test. Colours: White: vehicle, Dark blue: CagriSema, and grey: weight matched.CC BY-NC-ND · PubMed Central
Extended Data Fig. 6 Changes in plasma concentrations triiodothyronine (T3) and thyroxine (T4). Samples are from rats in main Fig. 1. a: T3 and b: T4, c and d: T3 and T4 at baseline (day −5) and by end of treatment (day 21), Data are shown as means ± SEM. Dots are individual rats. n = 6-8/group. Statistical significance was tested by Oneway ANOVA. ANOVA-value was in both cases non-significant (P > 0.05). Abbreviations: V: vehicle, CS: CagriSema, and WM: Weight matched.
Extended Data Fig. 6 Changes in plasma concentrations triiodothyronine (T3) and thyroxine (T4). Samples are from rats in main Fig. 1. a: T3 and b: T4, c and d: T3 and T4 at baseline (day −5) and by end of treatment (day 21), Data are shown as means ± SEM. Dots are individual rats. n = 6-8/group. Statistical significance was tested by Oneway ANOVA. ANOVA-value was in both cases non-significant (P > 0.05). Abbreviations: V: vehicle, CS: CagriSema, and WM: Weight matched.CC BY-NC-ND · PubMed Central
Extended Data Fig. 7 Principal component and pathway enrichment analysis. Samples are from main Fig. 2. a and b: Principal component analysis of liver (a) and skeletal muscle gene expression (b). (c-e) Pathway enrichment analysis of liver transcriptomes; c: V vs. CS, d: V vs. WM, and e: CS vs. WM (n = 8). Abbreviations: V: vehicle, CS: CagriSema, WM: Weight matched.
Extended Data Fig. 7 Principal component and pathway enrichment analysis. Samples are from main Fig. 2. a and b: Principal component analysis of liver (a) and skeletal muscle gene expression (b). (c-e) Pathway enrichment analysis of liver transcriptomes; c: V vs. CS, d: V vs. WM, and e: CS vs. WM (n = 8). Abbreviations: V: vehicle, CS: CagriSema, WM: Weight matched.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

3 Valid · 0 Not valid · 0 Not checked · 61 Own results and interpretations

25 more claims

Create a free account to see all 64 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 13
  • It may state two separate claims as one. 27

Create a free account to see these claims.

Citations

Cites

Show all 29 references

Cited by

See all 15

Metadata

Authors
Jacobsen, J. M., Halling, J. F., Blom, I., Moreno Martinez, J., Hald, B., Pedersen, K., Fels, J. J., Snitker, S., Secher, A., Lundh, S., le Roux, C. W., Raun, K., Reitman, M. L., & Kuhre, R. E.
Affiliations
  • Novo Nordisk (Denmark) (DK)
  • University of Copenhagen (DK)
  • National Institutes of Health (US)
Corresponding author
Kuhre, Rune Ehrenreich
Venue
Nature Metabolism
Published
2025-07-08
Volume
7
Issue
7
Pages
1322-1329
ISSN
2522-5812 (ISSN-L)
OpenAlex
W4412102616
Cited by
15
References
29
Citations by year
2026: 11 · 2025: 4
FWCI
6.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Metabolism (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
Funders
  • Novo Nordisk
  • Foundation for the National Institutes of Health (ZIA DK075062)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
cagrilintide, semaglutide, amylin analogues, GLP-1 analogues, weight loss, energy intake, energy expenditure, metabolic adaptation, obesity treatment, hypophagia, pair feeding
MeSH terms
Animals, Energy Intake, Eating, Energy Metabolism, Male, Obesity, Weight Loss, Rats, Glucagon-Like Peptide 1, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure. https://app.cochat.ai/papers/10.1038/s42255-025-01324-8
The paper
Jacobsen, J. M., Halling, J. F., Blom, I., Moreno Martinez, J., Hald, B., Pedersen, K., Fels, J. J., Snitker, S., Secher, A., Lundh, S., le Roux, C. W., Raun, K., Reitman, M. L., & Kuhre, R. E. (2025). CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure. Nature Metabolism. https://doi.org/10.1038/s42255-025-01324-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.